ADHD medications, start to finish

0:01Juno: Before we start: everything in this episode is information, not advice. The person to take it to is your medical doctor or your psychiatrist. Write your questions down while you listen. That's the whole point of it.

0:30Juno: This is The Observatory. Lone Star Telehealth pays for the telescope.

0:39Juno: No book today. This is the first of three reference episodes, and it's about the medications used for ADHD in adults.

0:48Beck: Start to finish. What they are, what the trials found, what the risks are, what they cost, and what to ask. It's chaptered, so if you only care about one medicine, skip to it.

1:02Juno: And I'm doing something different today. Usually I'm the reader. Today I'm the person with an appointment next week who's been told medication might come up, and who has questions.

1:15Beck: And I answer from the published evidence. Which means some answers will be a number with a method, and some will be, that's a question for your prescriber.

1:26Juno: Where's the evidence coming from?

1:28Beck: Two places. PubMed, the National Library of Medicine's index of medical research, and OpenEvidence, a search tool built for clinicians that reads the medical literature and points to the studies. Those are this show's two main resources. And nothing goes on air because either one said it. Every study they turn up gets checked against the published paper first.

1:52Beck: And there's a one-page sheet on the episode page that goes with this. It has every question you'll hear today, room to write, and a brief daily tracker for once you start. Print it now, or grab it after.

2:05Juno: Nobody's written to the mailbag yet, so every question today is mine.

2:10Beck: They're good questions. I've seen the list.

2:13Juno: One rule before we go in.

2:15Beck: Yeah. We don't rank them. When a study compares medications, we'll say what it measured, and that's where we stop.

2:31Juno: So start simple. What are we talking about?

2:35Beck: Two families, a newcomer, and a guest. The first family is the stimulants. There are two kinds: Ritalin and Concerta, which are methylphenidate, and Adderall and Vyvanse, which are amphetamines; Vyvanse is lisdexamfetamine. The second family is the non-stimulants approved for adults: Strattera, which is atomoxetine, and since 2022, Qelbree, which is viloxazine. The newcomer is Simtriyo, which is centanafadine, approved this summer, and it doesn't fit neatly in either family; we'll get to it. The guest is Wellbutrin, which is bupropion, an antidepressant that's sometimes prescribed for ADHD even though it isn't approved for it. That's called off-label, and we'll get to what that means.

3:23Juno: What about Intuniv? I've heard that one.

3:27Beck: Intuniv and Kapvay, the extended-release forms of guanfacine and clonidine, are approved for ADHD in children and teenagers, six to seventeen. Not in adults. A prescriber can still use them for an adult, off-label, and some do. The adult trial evidence for them is thinner, so we'll leave them there.

3:50Juno: So the brand is the name I'll recognize.

3:53Beck: Usually. So we'll say the brand the first time, then mostly the generic, because that's the name the studies use and the one on a generic bottle.

4:10Juno: Stimulants. What do they do?

4:12Beck: In the simplest terms, they raise the amount of two signaling chemicals, dopamine and norepinephrine, available between brain cells, in the circuits that manage attention and self-control. They work the day you take them, and they wear off the same day. That's what sets them apart from most psychiatric medicines.

4:33Juno: So no waiting six weeks to find out.

4:36Beck: No. Which is why the dose is usually adjusted step by step, over a few weeks, with the prescriber checking in. The other big difference between them is how long they last. Short-acting forms run a few hours. Long-acting forms are built to release over most of a day. Same medicine, different delivery.

4:56Juno: Do they work? In adults, I mean. Not kids.

5:01Beck: In adults, in short trials, yes. The largest analysis, from 2018, pooled a hundred and thirty-three double-blind randomized trials, fifty-one of them in adults, about eight thousand adults in the efficacy analysis. Measured by clinicians at around twelve weeks, both amphetamines and methylphenidate reduced core symptoms more than placebo.

5:26Juno: Measured by clinicians. What about the person taking it?

5:30Beck: Good question, and it matters. A 2025 analysis of adult trials looked at both kinds of rating separately. Stimulants beat placebo on the clinician's scale and on the person's own self-rating. That's not true of everything in that analysis, so it's worth knowing.

5:48Juno: And how sure is that?

5:51Beck: Sure enough to say they work in the short term, on average. Less sure than that sounds. A 2020 review that kept only the trials at the lowest risk of bias found the evidence for the whole group of medicines a good deal less certain. That doesn't overturn the finding. It's a reason to hold it with some care.

6:10Juno: And twelve weeks is short.

6:13Beck: It is. Most of the trial evidence is short term. What happens over years comes mostly from registries and health records, which can't randomize anybody. We'll get to those in the risks chapter, because they cut both ways.

6:28Juno: Side effects.

6:30Beck: The common ones in the trials are lower appetite, trouble sleeping, headache, dry mouth, and feeling jittery or on edge. Heart rate and blood pressure go up a little. A 2025 analysis of randomized trials measured that in adults: on average, two or three points of blood pressure and about four to six beats a minute of pulse above placebo, in trials that lasted around seven weeks. The certainty on those adult numbers was rated very low.

7:00Juno: A few points sounds small.

7:03Beck: On average it is. But an average can hide the people who rise more than that, and that's why a prescriber will ask about your heart and your family's heart, and take your blood pressure. That's the question on the sheet about heart history, and it's there for that reason.

7:19Juno: And people stopping because of side effects?

7:23Beck: In the 2018 analysis, adults on amphetamines and on methylphenidate were more likely than people on placebo to drop out of a trial because of side effects. More likely isn't most. It does mean the first dose isn't always the right dose, or the right medicine.

7:44Juno: Does a higher dose mean a bigger effect?

7:47Beck: Not in a straight line. A 2024 analysis of forty-seven adult trials, about seventy-seven hundred people, looked at dose. With methylphenidate, higher doses brought more symptom reduction, but each step added less, while dropouts for side effects kept rising. With the amphetamines, the benefit leveled off as doses went up, and the dropouts kept rising anyway. Those are group averages, and the authors say so. It's still a fair question to ask before a dose goes up.

8:22Juno: Okay. The thing people whisper about. Misuse.

8:27Beck: Stimulants carry an FDA boxed warning about misuse and addiction, and they're Schedule Two controlled substances, which is the reason for most of the pharmacy rules we'll get to. As for how common misuse is: a national survey from 2021 and 2022 looked at adults who used prescription stimulants. About a quarter reported some misuse in the past year, and in that survey misuse includes taking more, or more often, than prescribed. About nine percent met criteria for a use disorder, and most of those were using only their own prescription. Misuse and use disorder were both more common among people taking amphetamines than methylphenidate.

9:07Juno: Their own prescription.

9:09Beck: Yeah. Their own. Which is why a prescriber asks how you're taking it, not only whether you are.

9:25Juno: Before we go on. I've been taking notes and my question list is now longer than the episode.

9:32Beck: That's how it's supposed to work.

9:35Juno: Non-stimulants. Why would someone be on one?

9:39Beck: The reasons people are given vary. A stimulant didn't help or wasn't tolerated. There's a history that makes a controlled substance a harder conversation. Or a person would simply rather not take one. What we can do is say what these medicines are.

9:57Juno: Strattera first.

9:59Beck: Strattera is atomoxetine, and it raises norepinephrine. It isn't a controlled substance. And unlike a stimulant, it doesn't work the same day; the effect builds over weeks. In the 2018 analysis it beat placebo in adults on clinician ratings, and in the 2025 analysis it beat placebo on both clinician and self-ratings.

10:23Juno: Side effects?

10:25Beck: In the trials, nausea, lower appetite, trouble sleeping, and in some men, sexual side effects. In the 2018 analysis, adults on it were more likely than people on placebo to stop because of side effects. The 2025 cardiovascular analysis found it raises pulse too. It carries an FDA boxed warning about suicidal thoughts in children and teenagers; for an adult, it's still fair to ask what to watch for. Its label also warns about rare, severe liver injury. And some antidepressants, Prozac and Paxil among them, which are fluoxetine and paroxetine, change how it's broken down, so the dose may need adjusting.

11:08Juno: And Qelbree.

11:10Beck: Qelbree is viloxazine, in an extended-release form, and it was approved for adults in 2022. The adult trial behind that randomized three hundred and seventy-four people for six weeks. Symptom scores fell more on viloxazine than on placebo, and some of the difference showed up by week two. The most common side effects were trouble sleeping, tiredness, nausea, lower appetite, dry mouth and headache. Nine percent stopped because of side effects, against about five percent on placebo. It carries the same boxed warning as atomoxetine.

11:48Juno: That one's newer.

11:50Beck: Newer, with a smaller adult record than the older medicines. That's not a criticism; it's what the record holds. Fewer trials means wider uncertainty, and that's worth knowing when you ask about it.

12:03Juno: And it can interact with things?

12:06Beck: It can. It slows how the body clears some other medicines, which is true of several of these in one way or another. That's question six on the sheet: does this interact with anything on my list. Bring the whole list, caffeine included.

12:23Juno: And the newcomer.

12:25Beck: Simtriyo, which is centanafadine. The FDA approved it this summer, for adults and for children six and older. It works differently from the others: it blocks the reuptake of three signaling chemicals, norepinephrine, dopamine and serotonin, and its maker describes it as a central nervous system stimulant. In two six-week adult trials, about eight hundred and seventy-five people in all, symptom scores fell more than on placebo, by a small margin. The most common side effects its maker lists are headache, lower appetite, trouble sleeping, nausea, dry mouth and diarrhea.

13:02Juno: Can I get it?

13:03Beck: When it was approved, it was waiting on the DEA to decide how it's scheduled, and it reaches pharmacies after that. So the question is whether it's out yet, and what's known about it beyond six weeks. Newer means a shorter record.

13:25Juno: Off-label. That sounds like something's being snuck past someone.

13:31Beck: It isn't. A medicine gets FDA approval for specific uses, based on the trials the company submitted. Once it's on the market, a prescriber can legally prescribe it for something else when they judge the evidence supports it. That's off-label. It's common across medicine, and it's the prescriber's call.

13:50Juno: So Wellbutrin.

13:52Beck: Wellbutrin is bupropion, and it's approved for depression and for quitting smoking. It acts on dopamine and norepinephrine, which is why people looked at it for ADHD. In the 2018 analysis, bupropion beat placebo in adults on clinician ratings. The range around that estimate was wide, because there were fewer and smaller trials behind it. A 2017 Cochrane review of six trials, about four hundred and forty adults, rated the evidence low quality, found side-effect dropouts similar to placebo, and found nothing on long-term outcomes.

14:26Juno: Why would a prescriber reach for it?

14:29Beck: The reasons given in the literature are things like a person who also has depression, or who's quitting smoking, or for whom a controlled substance is a harder fit.

14:41Juno: Risks?

14:42Beck: It lowers the seizure threshold, more so at higher doses, so a history of seizures or of eating disorders is something the prescriber will ask about. And like all antidepressants, it carries an FDA boxed warning about suicidal thoughts in children, teenagers and young adults.

15:01Juno: And while we're on off-label, I've heard of people using Provigil.

15:07Beck: That's modafinil. The 2018 analysis included it, and in adults it did not beat placebo.

15:22Juno: Quick check. Is anyone else's notebook this full, or just mine?

15:28Beck: Just yours. Mine's a spreadsheet.

15:30Juno: Of course it is. Okay. Say the prescriber and I decide to try something. What do the first weeks look like?

15:39Beck: For a stimulant, usually a low dose to start, then changes every week or so, based on what you report and what the prescriber sees. For atomoxetine or viloxazine, a slower build, because the effect itself builds slowly.

15:55Juno: And how do I know if it's working? I don't trust myself to notice.

16:00Beck: That's the most useful thing you've said today. Most people can't judge it from memory, which is why the sheet has a tracking line. Once a day: the dose and the time you took it, how you slept, your appetite, focus on a scale of one to five, mood on a scale of one to five, and anything odd. A line a day is enough.

16:22Juno: That's it?

16:24Beck: That's it. And in the appointment, two weeks of those lines beat a general impression every time. You can also tie it to the specific things you wrote down before you went. The deadline that slipped, the bill that went unpaid. Is that happening less.

16:41Juno: What if it wears off at five o'clock and I fall apart at dinner?

16:46Beck: Then that's exactly what goes in the anything-odd column, with the time. Some people describe a dip as a stimulant wears off, and it's a common reason the timing or the form gets changed. It's a conversation, not a reason to tough it out.

17:01Juno: And missing a dose, or stopping?

17:05Beck: Question five on the sheet, and the answers differ by medicine. Some can be stopped any day and some shouldn't be stopped suddenly. Ask before it happens, not after.

17:25Juno: What if ADHD isn't the only thing? Anxiety, say. Or I'm not sleeping.

17:32Beck: Then say so first, not last. ADHD often comes with company: anxiety, depression, sleep problems, substance use. Each of those changes the conversation about which medicine, which dose, and which comes first. The prescriber can't factor in what they haven't heard.

17:52Juno: Even things I'm a little embarrassed about.

17:55Beck: Especially those. Alcohol, cannabis, nicotine, energy drinks, a supplement a friend swears by. The sheet says all of it, even the ones that feel unrelated, for a reason. Interactions are about what's in your body, not what you think counts.

18:14Juno: Pregnancy. Or planning one.

18:17Beck: That's a conversation to have with the prescriber, and ideally with whoever's caring for the pregnancy, before it comes up rather than after. One registry finding is worth knowing: a 2025 Swedish study of more than eight hundred and sixty thousand children found no higher rate of ADHD or autism in children exposed before birth to methylphenidate, amphetamines or atomoxetine. That answers one question. The ones about birth outcomes and breastfeeding are specific to each medicine. And there are psychiatrists who specialize in exactly this, perinatal or reproductive psychiatrists, who work with women taking these medicines who are pregnant or planning to be. It's worth asking for one.

19:03Juno: And if I've had a bad reaction to one of these before?

19:06Beck: Bring the name, the dose if you know it, and what happened. A bad reaction to one doesn't mean a bad reaction to all of them. It does mean the prescriber needs to know.

19:25Juno: Okay. The longer-term questions. The ones people look up at night.

19:31Beck: Before we start, one thing about method. Almost everything in this chapter comes from registries and health records, not randomized trials. Those studies follow huge numbers of people for years, which trials can't do. But they can't fully separate the medicine from the reasons some people take it and others don't. So every number here is an association, and they point in both directions.

19:55Juno: Heart first.

19:56Beck: A 2024 Swedish study compared about ten thousand people with ADHD who developed cardiovascular disease with about fifty thousand who didn't. The longer people had taken ADHD medication, the higher the odds of cardiovascular disease. Each additional year of use went with about four percent higher odds, mostly in the first three years, and mostly high blood pressure and arterial disease.

20:22Juno: Four percent higher than what?

20:25Beck: Than people with ADHD who didn't take medication over the same period. It's a relative number about groups, and it's a reason to keep the follow-up appointments and the blood pressure checks.

20:36Juno: Psychosis. I've seen headlines.

20:40Beck: This one gets more fear than it should, so let's be careful with it. It's uncommon, and much of what people have heard comes from illegal methamphetamine, which is a different situation from a prescribed dose. A 2013 study that followed people dependent on methamphetamine found psychotic symptoms about five times as likely in the months they were using, and more with heavier use.

21:06Beck: For prescriptions, the signal is smaller and tied to dose. A 2024 study at one psychiatric hospital compared people aged sixteen to thirty-five admitted for a first episode of psychosis or mania with people admitted for other reasons. Past-month prescription amphetamine use went with higher odds, and the odds rose with dose; the highest doses had the strongest association. Methylphenidate wasn't associated with higher odds in that study. The authors note their design had a selection bias, and their advice was caution with high doses and regular screening. A 2025 review of sixteen studies, mostly children and teenagers, found a psychotic disorder in about two percent of people treated with stimulants, more often with amphetamines and at higher doses. It can't show the stimulant caused it, and its authors say prescribers should tell people about it and keep watching for it.

22:04Juno: That's a lot of bad news in a row.

22:07Beck: Then here's the other direction, by the same kind of method. A US study of more than two million people with ADHD compared each person with themselves: months on medication against months off. Emergency visits for car crashes were about forty percent lower in the medicated months, for men and for women.

22:31Juno: Compared with themselves. That's clever.

22:35Beck: It removes a lot of the differences between people, because it's the same person. And a 2024 Swedish study of about a hundred and fifty thousand people newly diagnosed found that starting medication went with lower deaths over the next two years, about thirty-nine per ten thousand against forty-eight, driven by fewer deaths from injuries, poisonings and suicide.

23:02Juno: Is that holding up?

23:03Beck: Mostly, with a wrinkle. A 2025 Swedish study of about two hundred and forty-seven thousand people, again each compared with themselves, found lower rates of self-harm, injuries, traffic crashes and crime in the periods when people were taking their medication. But between 2006 and 2020, as prescribing rose, the lower rates for injuries, crashes and crime got smaller. The authors' point was that the benefit should be checked again as more people take these.

23:36Juno: So the long-term record has a cost and a benefit, and both are associations.

23:43Beck: Yeah. Both are associations, from big populations, about groups. Which is why the question to bring isn't, is this safe. It's, what are we watching for in my case, and how often.

24:05Juno: Practical part. I'm told the pharmacy is its own adventure.

24:11Beck: It has a phone tree.

24:12Juno: Of course it does.

24:16Beck: It can be. Because stimulants are Schedule Two, a prescription can't have refills. Each fill needs its own prescription. Federal rules let a prescriber write several prescriptions at once, with dates on them, covering up to ninety days, where state law allows and if they decide it's appropriate.

24:35Juno: That sounds like a lot of moving parts.

24:38Beck: It is, so two habits help. Keep an eye on how many days you have left and start the refill a few days early, so a delay doesn't leave you without. And if calls and follow-ups are hard for you, let a friend or partner help with them. Plenty of people do.

24:57Juno: And if the pharmacy doesn't have it?

24:59Beck: Call before you go. Ask whether they have that medicine, in that strength and form, before the prescription is sent. If they don't, the prescriber can usually send it somewhere else. The non-stimulants and bupropion aren't controlled, so they work like most prescriptions.

25:17Juno: And if my prescriber is a telehealth practice?

25:21Beck: Then ask how they handle controlled substances. The federal rules for prescribing them by video have been temporary for years and keep getting extended. Ask what happens to your prescription if those rules change, and whether you'd ever need an in-person visit.

25:37Juno: Cost.

25:38Beck: We don't say prices, because they change and they vary by pharmacy, by plan and by form. What we say is: check GoodRx before you fill anything. Ask whether there's a generic; the newest medicines usually don't have one. Ask whether a different form, short-acting or long-acting, costs much less. And ask whether your plan needs prior authorization, which is paperwork the prescriber's office files before the plan will pay. It's common with these, and it's a reason a first fill sometimes takes a few days.

26:11Juno: And the manufacturer coupon cards?

26:15Beck: Some brand-name medicines have them, and they can lower the cost for people with commercial insurance. Read the terms; they usually have limits. Again, GoodRx and the pharmacist are the place to compare.

26:35Juno: Last chapter. What do I bring?

26:39Beck: The sheet. The first half isn't questions at all. It's things to write down before you go: what a weekday looks like and where it comes apart, two or three recent examples and what they cost you, what you've already tried, everything you take, including caffeine, alcohol and cannabis, how you sleep, and your heart and family history. And bring any psychological testing you've had, the report itself if you have it.

27:08Juno: Why write it down? I know my own life.

27:12Beck: Because in a short appointment, it's easy to describe your best week instead of a typical one. The examples are what let a prescriber see the rest of it.

27:23Juno: And the questions themselves.

27:25Beck: The ones that came up today: what is this meant to change for me, and how will we know. What's normal in the first two weeks, and what should make me call the same day. How the dose is decided. Does it interact with anything on my list. Is there a generic, and what does it cost. What happens to sleep, appetite and mood. And if this one isn't right, what's next, and how long before we decide.

27:53Juno: And one more for the people who aren't sure they want any of it.

27:58Beck: Question twelve. If I'd rather not take medication, what else is on the table. In the 2025 adult analysis, cognitive behavioral therapy, psychoeducation and mindfulness did better than control conditions on clinician ratings, though not on the person's own ratings. And a 2026 analysis of therapy for adults found improvements in daily functioning that were larger at follow-up than at the end of treatment.

28:25Juno: So you've done the caveat in pieces all episode. Do it whole.

28:32Beck: Happily. Nobody on this show prescribes, recommends, ranks or compares medications, and today was no exception. We reported what the studies measured. Your prescriber is the expert, and the conversation with them is the one that counts. What a therapist adds is the part before it: helping you walk in able to say how your days go, accurately, which turns out to be the hardest part, and the most common reason people leave those appointments with less than they came for.

29:08Juno: Logan, again.

29:10Beck: Logan, again. It's how he handles this conversation with the people he sees, and he'd like it to be how every therapist does. And he wanted this episode made as something to point people to before that appointment.

29:24Juno: And deciding not to take anything at all?

29:27Beck: Gets the same respect as deciding to. Medication is a frontline treatment, and this episode isn't going to pretend otherwise. It's also a choice, and the choice is the person's.

29:43Juno: So, my appointment's next week. I have a sheet, a list of everything I take, three examples, and twelve questions.

29:52Beck: That's a well-prepared patient.

29:54Beck: Next time, back to the books. NeuroTribes. Steve Silberman. Who named autism, and what did they get wrong.

30:03Juno: From pharmacology to history. I'll take it.

30:07Juno: That's us.

30:08Beck: That's us. Go outside.

30:11Beck: Everything in this episode is reported from the published evidence and none of it is a recommendation. Take your questions to your medical doctor or your psychiatrist. They know you, they can prescribe, and we cannot do either.

30:26Juno: For prices, check GoodRx before you fill anything. The Observatory is produced by Lone Star Telehealth. Logan Williamson is a Licensed Professional Counselor in Texas and Louisiana. This is education, not counseling, and not a substitute for care. Chapters and sources are on the episode page.

30:55Juno: One more thing, said plainly. Juno and Beck are synthetic voices. We are not people, we are not licensed, and nothing we said is about you. The scripts are written with AI assistance and are edited and approved by Logan Williamson, a Licensed Professional Counselor in Texas and Louisiana, at Lone Star Telehealth.